Effect of ursodeoxycholic acid on TGF beta1/Smad signaling pathway in rat hepatic stellate cells

Chinese Medical Journal

Volumn 122, Issue 10, 2009, Pages 1209-1213

  Liang, Tie Jun ^a   Yuan, Jun Hua ^a   Tan, Yan Rong ^a   Ren, Wan Hua ^a   Han, Guo Qing ^a   Zhang, Jie ^a   Wang, Lai Cheng ^a   Qin, Cheng Yong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Hepatic stellate cells; Transforming growth factor beta1 Smad signaling pathway; Ursodeoxycholic acid

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; SMAD PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; LIVER CELL; LIVER FIBROSIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CHOLAGOGUES AND CHOLERETICS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HEPATIC STELLATE CELLS; HUMANS; POLYMERASE CHAIN REACTION; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

EID: 68249141226     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.10.018     Document Type: Article

References (32)

1. Li YR, Wei L. Mechanism of transforming growth factor beta/Smad signaling and the relationship between its transduction and liver fibrosis. Chin J Hepatology (Chin) 2005; 6: 476-478.
2. Jiang H, Li DG. TGF-β1 and hepatic fibrosis. World Chin J Digestol (Chin) 2003; 3: 326-329.
3. Liao D, Jiang JN. The mechanism in formation of hepatic fibrosis. Epidemiol Lemology Foreign Med Sci (Chin) 2004; 3: 170-172.
4. Wu XL, Zeng WZ, Jiang MD, Wang PL. Research progress in signal transduction pathway of liver fibrosis. World Chin J Digestol (Chin) 2006; 22: 2223-2228.
5. Liu X, Wei HS, Lin S. Signal transduction of hepatic stellate cells in liver fibrosis. J Med Mol Biol 2006; 5: 361-363.
6. Meurer SK, Tihaa L, Lahme B, Gressner AM, Weiskirchen R. Identification of endoglin in rat hepatic stellate cells: new insights into transforming growth factor beta receptor signaling. J Biol Chem 2005; 280: 3078-3087.
7. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF beta receptor signaling and turnover. Nat Cell Biol 2003; 5: 410-421.
8. Calabrese F, Valente M, Giaeometti C, Pettenazzo E, Benvegnu L, Alberti A, et al. Parenchymal transforming growth factorβ1: Its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. J Gastroenterol Hepatol 2003; 18: 1302-1308.
9. Qin BY, Lam SS, Correia JJ, Lin K. Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev 2002; 15: 1950-1963.
10. Xu L, Alarcon C, Col S, Massague J. Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import. J Biol Chem 2003; 43: 42569-42577.
11. Chen YW, Chen YW, You HN, Li DG.. The effect of exogenous Smad7 gene on activation of hepatic stellate cell in primary culture and its role in the regulation of geng expression. Chin J Dig (Chin) 2005; 7: 409-421.
12. Osawa H, Nakajima M, Kato H, Fukuchi M, Kuwano H. Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Anticancer Res 2004; 6: 3703-3709.
13. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004; 3: 251-261.
14. Jinnin M, Ihn H, Mimura Y, Mimura Y, Tamaki K. Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor beta signaling in scleroderma fibroblasts. Arthritis Rheum 2007; 5: 1694-1705.
15. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodexycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8: 67-81.
16. Li L, Xu X, Lu F, Zhao N. Effects of ursodeoxycholic acid on intrahepatic cholestasis in rats. Chin Med J 2003; 7: 1099-1103.
17. Perez MJ, Macias RI, Duran C, Monte MJ, Gonzalez-Buitrago JM, Marin JJ. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol 2005; 2: 324-332.
18. Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 2: 297-303.
19. Leuschner M, Holtmeier J, Achemann H, Leuschner U. The influenec of sulinac on patients with primary biliary cirrhosis that responds inconmpletely to Ursodeoxycholic acid:a pilot study. Eur J Gastrenterol Hepatol 2002; 12: 1369-1376.
20. Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 3: 217-226.
21. Paumgartner G, Beuers U. Ursodeoxychlic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 3: 525-531.
22. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 6: 318-328.
23. Copaci I, Micu L, Iliescu L, Voiculescu M. New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol 2005; 3: 259-266.
24. Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005; 2: 135-145.
25. Liang KH, Li Q, Wang Y, Tang WX, Zhang G, Wang TC. Relationship between different expressions of Smad3, Smad7 genes and liver fibrogenesis. Chin J Dig (Chin) 2002; 11: 647-650.
26. Song S, Gong ZJ, Zhang QR. Expression of TGF1 and its receptors, Smad3 andSmad7 in rats with experimental liver fibrosis. World Chin J Digestol (Chin) 2004; 3: 676-679.
27. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alphy-smooth muscle actin organization. Mol Biol Cell 2005; 16: 4214-4224.
28. Tao YY, Cui HY, Liu CH. Dynamic characteristics of SARA during liver fibrogenesis in rats. Chin J Hepatology (Chin) 2006; 12: 909-913.
29. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, et al. Differential regulation of TGFβ signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35: 49-61.
30. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, et al. Arkadia amplifies TGF beta super family signaling through degradation of Smad7. EMBO J 2003; 24: 6458-6470.
31. Kitamura Y, Ninomiya H. Smad expression of hepatic stellate cells in liver cirrhosis in vivo and hepatic stellate cell line in vitro. Pathol Int 2003; 53: 18-26.
32. Ruan YH, Liu HL. Smad7 and liver fibrosis. Int J Dig Diseases (Chin) 2007; 3: 208-210.